

Technology Advisory Committee A Interests Register

Topic: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer [ID1644]

Publication Date: 20/04/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alice Turner	Committee member	Direct financial	Dr Turner has received consultancy and honoraria fees from GSK In an unrelated area.	N/A	July 2021	N/A	It was agreed that her declaration would not prevent Dr Turner from participating in discussions on this appraisal.
Professor Jonathan Ledermann	Clinical expert	Direct & Indirect financial	Professor Ledermann has previously received advisory board and lecture fees from Neopharma, GSK, AstraZeneca, Clovis Oncology, Eisai, MSD, Artios Pharma, Regeneron, VBL Therapeutics and Pflzer. His university has received research grants from AstraZeneca and MSD. He was the clinical Investigator on trials with niraparib, olaparib and rucaparib in recurrent ovarian cancer and he is also editor of Gynaecological Cancer	N/A	June 2021	N/A	It was agreed that his declarations would not prevent Professor Ledermann from providing expert advice to the committee.

			Track, ESMO Clinical Practice Guidelines and Vice President of ESGO.				
Rachel Downing	Patient expert	Direct & Indirect financial	Target Ovarian Cancer has received funding from GSK In May 2020 for the nurse-led support line as part of Its response to the coronavirus pandemic. They also received funding In August 2020 from AstraZeneca for the running of Target Ovarian Cancer's nurse-led support line and online support to women as part of the response to the coronavirus pandemic. Rachel received an honorarium for a speaking engagement from GSK.	N/A	May 2021	N/A	It was agreed that her declarations would not prevent Rachel from providing expert advice to the committee.